cas 57267-03-5|| where to buy Ethyl 2,2,2-triethoxyacetate

Produktname:Ethyl 2,2,2-triethoxyacetate

IUPAC Name:ethyl 2,2,2-triethoxyacetate

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM253734-1g	in stock	ƥȐƥ
CM253734-5g	in stock	ȐƛȺ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 57267-03-5 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:57267-03-5; Molekulare Formel:C10H20O5; Schmelzpunkt:-; SMILES-Code:CCOC(=O)C(OCC)(OCC)OCC; Dichte:

: Katalognummer:CM253734; Molekulargewicht:220.27; Siedepunkt:267.9°C at 760 mmHg; Mdl-Nr.:MFCD00449653; Lagerung:Store at room temperature

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: NT-0796; NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s Disease phase Ib/IIa trial. The positive data from its Phase Ib/IIa study indicates that NT-0796 reduces key neuroinflammatory and inflammatory biomarkers in Parkinson’s disease patients to the levels found in healthy elderly controls over 28 days.
The NLRP3 inflammasome is a main mediator of inflammation in many pathologies. NT-0796 selectively inhibits NLRP3, lowering levels of both pro-inflammatory cytokines IL-1β and IL-18. This action delivers therapeutic effects directly to immune cell types responsible for inflammatory diseases, including peripheral and neuroinflammatory diseases.